HistoSonics has obtained approval from Taiwan’s Food and Drug Administration for its Edison Histotripsy System, an advanced, non-invasive device designed to eliminate tumours using focused ultrasound waves. This groundbreaking technology destroys cancerous tissue without the need for surgery, radiation, or heat, minimizing patient risk. The TFDA’s authorization, announced on 18 May, represents a pivotal milestone in HistoSonics’ strategic expansion across Asian markets and marks Taiwan as a key region in its growth plan.
Back
